First-line systemic treatment of psoriasis: staying conventional or going biologic? - Wikidata - awgldk - TriplyDB

First-line systemic treatment of psoriasis: staying conventional or going biologic?

First-line systemic treatment of psoriasis: staying conventional or going biologic?

http://www.wikidata.org/entity/Q48156161

about

First-line systemic treatment of psoriasis: staying conventional or going biologic?

http://www.wikidata.org/entity/Q48156161

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@en

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@nl

type

label

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@en

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@nl

prefLabel

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@en

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@nl

P1433

Q48156161-1432E864-23A4-47B1-9E67-7D2304AACDC6

P1476

Q48156161-605B9392-BC3F-4E86-A5AC-15D677FD13C2

P2093

Q48156161-1710FE91-2345-42A3-B758-C5B383ABCE05

P2860

Q48156161-0244A22D-7A1B-4244-989D-352FBA105595

Q48156161-56C56947-331D-41DE-B73B-C55C4A58DCE0

Q48156161-58F0DF0A-3716-480C-A060-840B4C3F8F65

Q48156161-5C8A4386-393B-4937-8B9F-B6A2B47401F1

Q48156161-62B1A9C2-F11D-41D8-9F0A-D0E970B58023

Q48156161-745DBFA7-0F6F-4A4F-8DE9-8F98AA7B0C30

Q48156161-76454F78-8239-4722-8DCF-8CDBC997BBA3

Q48156161-7BCBB097-F663-4528-967C-7921DEABF7E5

Q48156161-7F9A9F77-4432-4FEC-9611-2BDC88C70B9F

Q48156161-F0AB6876-B933-4A0D-8CF3-3F5591B93D0E

P304

Q48156161-ED5415C3-0283-42B9-910D-E4A2553D8989

P31

Q48156161-81A6A1F9-C0DF-4BF8-A787-726D8B79F2F9

P356

Q48156161-E200F905-5B43-4C87-9739-3E711A382058

P407

Q48156161-9885BB17-BACA-4F49-9617-0783C7D7D636

P433

Q48156161-6AC466ED-E6E6-4D8E-98EB-80D4117538B0

P478

Q48156161-F26E9574-EC77-4DDD-9F8C-270609238038

P50

Q48156161-29C5C938-5F6B-4381-98CF-6A149515F84E

P577

Q48156161-24A91276-B611-4CB3-BDFF-C81A63159AD5

P698

Q48156161-55312FB4-214E-44FC-A441-E2C27B9DB3CE

P356

P1433

British Journal of Dermatology

P1476

First-line systemic treatment of psoriasis: staying conventional or going biologic?

@en

P2093

D M W Balak

http://www.w3.org/2001/XMLSchema#string

P2860

Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks.

The translational revolution and use of biologics in patients with inflammatory skin diseases.

Biosimilars for Psoriasis: Worldwide Overview of Regulatory Guidelines, Uptake and Implications for Dermatology Clinical Practice.

Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis.

British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017.

Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris.

Drug survival of fumaric acid esters for psoriasis: a retrospective study.

Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial.

European S3-Guidelines on the systemic treatment of psoriasis vulgaris--Update 2015--Short version--EDF in cooperation with EADV and IPC.

P304

897-898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJD.15885

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

177

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29052873

http://www.w3.org/2001/XMLSchema#string